Advertisement

SABCS 2020: Radiotherapy Omission After Breast-Conserving Surgery for Older Patients With HR-Positive Breast Cancer


Advertisement
Get Permission

Patients aged 65 or older with hormone receptor (HR)-positive breast cancer who did not receive radiation therapy after breast-conserving surgery had higher rates of local recurrence but similar 10-year survival rates when compared to patients who received postoperative radiation therapy, according to updated 10-year data from the PRIME II study, presented by Ian Kunkler, FRCR, and colleagues at the 2020 San Antonio Breast Cancer Symposium (Abstract GS2-03).

“Over half the patients diagnosed with breast cancer in developed countries are over the age of 65 years,” said Dr. Kunkler, Professor of Clinical Oncology at the Western General Hospital, University of Edinburgh. Despite the less-aggressive breast cancers typically diagnosed in this population, most patients who undergo breast-conserving surgery continue to be treated with whole-breast radiation therapy after surgery, he explained.

Ian Kunkler, FRCR

Ian Kunkler, FRCR

“We were interested in determining whether older patients with low-risk breast cancer could be spared radiation therapy,” added Dr. Kunkler.

PRIME II Details

The PRIME II study enrolled 1,326 patients with nonmetastatic HR-positive breast cancer. All patients were at least 65 years of age, had undergone breast-conserving surgery, and were receiving adjuvant hormone therapy. Patients were randomly assigned to either receive or not receive radiation therapy after surgery.

Dr. Kunkler and colleagues previously reported findings from the trial in The Lancet that showed greater rates of local recurrence (defined as recurrence in the same breast as the primary tumor) in patients who did not receive radiation therapy, but no significant differences in overall survival, distant metastases, or new breast cancers between the two arms after 5 years.

10-Year Follow-up Results

The latest data presented at the 2020 San Antonio Breast Cancer Symposium include results from a 10-year follow-up. Dr. Kunkler reported that the rate of local recurrence after 10 years was significantly greater in patients who did not receive radiation therapy compared with patients who did (9.8% vs 0.9%).

While postoperative radiation therapy affected the risk of local recurrence, it did not significantly impact certain other clinical outcomes. After 10 years, patients who did not receive radiation therapy had similar rates of distant metastasis (1.4% vs 3.6%), recurrence in the opposite breast (1.0% vs 2.2%), and overall survival (80.4% vs 81.0%) as patients who did receive radiation therapy. Most deaths were due to reasons other than breast cancer.

KEY POINTS

  • The rate of local recurrence after 10 years was significantly greater in patients who did not receive radiation therapy compared with patients who did (9.8% vs 0.9%).
  • After 10 years, patients who did not receive radiation therapy had similar rates of distant metastasis (1.4% vs 3.6%), recurrence in the opposite breast (1.0% vs 2.2%), and overall survival (80.4% vs 81.0%) as patients who did receive radiation therapy.

“We found that omitting postoperative radiation therapy did not compromise survival or increase the risk of distant metastasis,” said Dr. Kunkler. “Based on these results, we believe that omission of radiation therapy after breast-conserving surgery should be an option for older patients with localized, HR-positive breast cancer who are receiving adjuvant hormone therapy and meet certain clinicopathologic criteria.”

A limitation of the study is that only a few patients with grade 3 tumors were recruited, so the results of the study may not be applicable to patients with high-grade tumors or with tumors larger than 3 cm. An additional limitation is that data on comorbidities or adherence to adjuvant hormone therapy were not collected.

Disclosure: The study was supported by the Chief Scientist Office for Scotland and the Edinburgh Breast Cancer Institute NHS Endowment Fund. Dr. Kunkler declared no conflicts of interest.

The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.
Advertisement

Advertisement



Advertisement